Long if it breaks the high of the previous day with a stop loss at the previous day's low.
Short if it breaks the low of the previous day with a stop loss at the previous day's high.
In case of gap up above the previous day's high or gap down below the previous day's low, please avoid buying it or selling it respectively. Follow the ending of the candle formed...
Key Levels for CIPLA are : t.me - JOIN TELEGRAM CHANNEL
Upper Breakout~475
Interim Resistance~481.50
Final Resistance~486
**Lower Levels**
Lower Breakout~468
Interim Support~462
Final Support~455
Please trade with caution and consult your financial adviser before trading. You can also join our TELEGRAM channel from the below mentioned...
Cipla is in the verge of ascending triangle breakout. Recently high volume buying is seen as well. Breakout will be confirmed above 468 levels; above which stock may test 484/500+ levels.
Cipla (Monthly time frame) is close to a breakdown level 470. Sustaining below that (monthly closing basis only) will see further acceleration in downtrend. The next major support is at 425-400 below this level.
NSE:CIPLA
Only for education and information purpose. Should not be taken as a trading call
We can go long at D point.
CHART BY HARMONIC LEARNING AND EARNING
check the chart for further details
on 7th august results announced with net profit @447.15cr vs 445.61cr
not as expected hence stock came down back to the support
i think its the best time to invest
please take it for educational purpose or for paper trading !!!!!!!!
Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
CIPLA
